United Kingdom· GB-APID-40637511000001103
Tenkasi 400mg powder for concentrate for solution for infusion vials
A oritavancin product containing oritavancin, registered in United Kingdom by A. Menarini Farmaceutica Internazionale SRL. The same ATC class is registered in 12 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Oritavancin is registered in 12 of 19 countries.
Countries holding a registration under ATC J01XA05 (oritavancin), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Oritavancin · ATC J01XA05
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Oritavancin
- Manufacturer
- A. Menarini Farmaceutica Internazionale SRL
- Country
- United Kingdom (GB)
- ATC code
- J01XA05
- ATC class
- Oritavancin
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5038227000058
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
68 interactions on record for oritavancin.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Oritavancin · interactions on record
68 records
- 2 severe
- 64 moderate
- 2 minor
Most severe, free to view
- HeparinB01AB01severe
- HeparinB05CX05severe
- Sodium picosulfateA06AB08moderate
- NitisinoneA16AX04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Oritavancin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTenkasi 400 mgMenarini International Operations Luxembourg
- CzechiaTENKASIMenarini International Operations Luxembourg S.A., Luxembourg
- SpainTENKASI 400 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMenarini International Operations Luxembourg S.A.
- IrelandTenkasi 400 mg powder for concentrate for solution for infusionMenarini International Operations Luxembourg S.A.
- PolandTenkasiMenarini International Operations Luxembourg S.A.
- United StatesKimyrsaMelinta Therapeutics, LLC
- SwitzerlandTenkasi 1200 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungA. Menarini GmbH
- FranceTENKASI 1200 mg, poudre pour solution à diluer pour perfusionMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tenkasi
- Liechtenstein · Tenkasi
- Norway · Tenkasi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8a8caac3-d241-4d87-a3ef-63a0f93f9477 GET /v1/drugs/8a8caac3-d241-4d87-a3ef-63a0f93f9477?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40637511000001103",
"desc": "Tenkasi 400mg powder for concentrate for solution for infusion vials (A. Menarini Farmaceutica Internazionale SRL)",
"form": "Powder for solution for infusion",
"vpid": "40651511000001105",
"source": "dmd",
"vtm_id": "777001001",
"strength": "400 mg",
"substance": "Oritavancin",
"ingredient": "Oritavancin diphosphate",
"supplier_code": "3533901000001105"
}See everything about oritavancin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.